Editorial · 27 Aug 2020
EditorialPublished 27 Aug 2020
FDA Considers Sertindole, a SecondGeneration Antipsychotic
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Sertindole, an antipsychotic that was previously reviewed by the United States Food and Drug Administration (FDA) in the late 1990s, has recently been submitted as a new drug application for consideration for approval as a treatment for schizophrenia
Keywords
Subjects
Mental Health and PsychologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Other · 2013
New Antipsychotic Drug Submitted to FDA
Article · 18 Mar 2026
Antipsychotics vs. ECT with Antipsychotics: A PANSS and SCORS Investigation in Paranoid Schizophrenia
Perspective · 29 Jun 2025
The Impact of Antipsychotic Medications on Executive Functioning in Bipolar Disorder
Article · 29 Oct 2024
The Role of Medication in Managing Mixed Mood Episodes: Antidepressants, Antipsychotics and Mood Stabilizers
More from this journal
The newest in Clinical Schizophrenia & Related Psychoses.
Article · 18 Mar 2026
Antipsychotics vs. ECT with Antipsychotics: A PANSS and SCORS Investigation in Paranoid Schizophrenia
Article · 30 Sep 2025
Successful Treatment of a Treatment Refractory Patient with Clozapine Retrial
Article · 24 Jun 2025
Check the Necessity of Performing A CT Scan of the Brain in Patients with Mild Trauma
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Schizophrenia & Related Psychoses
- SubjectMental Health and Psychology
- BylineArticles whose byline prints “Peter F. Buckley”

